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Abstract: Currently available test methods are not well-suited for the identification of chemicals that 
disturb hormonal processes involved in female reproductive development and function. This 
renders women’s reproductive health at increasing risk globally, which, coupled with increasing 
incidence rates of reproductive disorders, is of great concern. A woman’s reproductive health is 
largely established during embryonic and fetal development and subsequently matures during 
puberty. The endocrine system influences development, maturation, and function of the female 
reproductive system, thereby making appropriate hormone levels imperative for correct 
functioning of reproductive processes. It is concerning that the effects of human-made chemicals on 
the endocrine system and female reproductive health are poorly addressed in regulatory chemical 
safety assessment, partly because adequate test methods are lacking. Our EU-funded project FREIA 
aims to address this need by increasing understanding of how endocrine disrupting chemicals 
(EDCs) can impact female reproductive health. We will use this information to provide better test 
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methods that enable fit-for-purpose chemical regulation and then share our knowledge, promote a 
sustainable society, and improve the reproductive health of women globally. 
Keywords: female reproductive health; endocrine disrupting chemicals; test methods; risk 
assessment; fertility; ovary; oocyte; adrenal; mammary gland; steroidogenesis; bioassay 
 
1. Introduction 
The number of women with reproductive health problems is increasing globally and scientific 
knowledge clearly points towards exposure to human-made chemicals being a contributing factor. It 
is clear that many chemicals in our food and the environment can disrupt endocrine processes and 
thereby threaten the reproductive health of humans, livestock, and wildlife globally [1]. These 
chemicals are collectively called endocrine disrupting chemicals (EDCs): “an exogenous substance or 
mixture that alters function(s) of the endocrine system and consequently causes adverse health effects 
in an intact organism, or its progeny, or (sub) populations” [2]. Numerous concerns about 
reproductive effects in humans and wildlife originate from findings linking exposure to EDCs in the 
womb to testicular dysgenesis syndrome, characterised by declining sperm counts and increasing 
prevalence of undescended testes, testicular cancer, and urinary duct malformation in males [3]. 
However, in contrast to male reproduction, we know surprisingly little about the mechanisms by 
which EDCs can impair female reproduction. Inevitably, therefore, the definition of ovarian 
dysgenesis syndrome is much more loosely encompassed [4]. This incomplete knowledge about 
cause–effect relationships between chemical insult and disease manifestation in women is partly the 
reason why we lack good test methods to address this in regulatory chemical risk assessment practice. 
In addition, the development of internationally recognised test methods has not kept up with the 
increasing scientific knowledge base. This means that women, and society more broadly, are not 
properly protected against potentially harmful chemicals that we encounter in our daily lives. The 
project FREIA (http://www.freiaproject.eu), funded under the EU Horizon 2020 programme, aims to 
address this pressing problem. Together with seven other projects, FREIA is part of the cluster 
EURION: European Cluster to Improve Identification of Endocrine Disruptors (http://www.eurion-
cluster.eu). 
The core objective of FREIA is to provide improved testing capabilities for the identification of 
EDCs that are harmful for female reproduction, as is expressed in the full project title “Female 
Reproductive toxicity of EDCs: a human evidence-based screening and Identification Approach”. 
European law requires chemicals to go through a safety evaluation before being allowed on the 
market. Regulators assess the endocrine disrupting properties of a chemical mostly based on data 
from standard test protocols that are agreed upon by the Organisation for Economic Co-operation 
and Development (OECD) and described in the Guidance Document on Standardised Test 
Guidelines for Evaluating Chemicals for Endocrine Disruption (OECD GD150) [5]. Unfortunately, 
currently available protocols are not well-suited for detection of EDC effects on important health 
outcomes, including endpoints concerning the female reproductive system. Standardised test 
guidelines for in vivo toxicity testing mainly cover gross, observational endpoints. These include 
ovarian morphology, primordial follicle counts, oestrous cyclicity, or indirect indices of female 
reproduction, such as pregnancy rate and pup survival. The available standardised in vitro and in 
silico bioassays within OECD GD150 focus mainly on effects related to (o)estrogen-androgen-
thyroid-steroidogenesis (EATS) modalities. Clearly, these endpoints are too limited and do not take 
into full consideration the effects on the female reproductive system as a result of early life exposure 
to chemicals—i.e., in the womb, during infancy and puberty—when a female body is still under 
development. Nor do they consider lifelong exposures and (premature) reproductive senescence. In 
this project report, we will first briefly describe the sensitive windows during female development 
and how exposure to EDCs during these life stages may lead to female reproductive toxicity. 
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Thereafter, we will highlight some gaps in current test strategies for EDC identification along with 
the FREIA project strategy to address this. 
2. EDC Exposure and Female Reproductive Disorders: The Current State of Knowledge 
The FREIA project focuses in particular on effects related to ovarian function, including the role 
of various steroid hormones and gonadotropins. The project also comprises the development of the 
mammary gland from the fetal stage to adulthood, because mammary gland development is known 
to be a sensitive endpoint for EDC identification. We acknowledge that this is only part of what 
constitutes ‘female reproductive health’. 
2.1. Female Reproductive Health 
Good reproductive health is important for the health and well-being of women and, if they wish 
to conceive, for the health of their children and future generations. Estimations show that up to one 
in six couples in Western countries experience problems conceiving or carrying pregnancy to term; 
however, the prevalence of subfertility varies widely between studies due to differences in study 
design and classifications [6]. A woman's fertility decreases as she gets older, but even during her 
most fertile years, lifestyle choices and external factors can affect her chances of having a healthy 
baby. Ovulation disorders account for infertility in about 1 in 4 infertile couples. Examples of 
ovulation disorders are polycystic ovary syndrome (PCOS) and primary ovarian insufficiency (POI) 
also known as premature ovarian failure (POF). A disrupted hormone balance is a clear manifestation 
of these disorders and often appears to be an underlying mechanism in the aetiology. Therefore, it is 
not surprising that exposure to EDCs is associated with reduced female fertility and ovarian 
disorders. For example, epidemiological studies show that women with PCOS have higher levels of 
bisphenol A (BPA) [7], and perfluorooctanoic acid and perfluoro-octanesulfonate [8] compared to 
women without PCOS. There are strong indications to link EDC exposure to POI, however, except 
for cigarette smoking, there is a lack of relevant human data addressing this [9]. Furthermore, 
disturbances of hormone levels—e.g., by BPA [10]—can cause menstrual cycle irregularities as well 
as affect the quantity and quality of available oocytes. 
2.2. Characterisation of Susceptible Windows 
A woman’s reproductive health is largely established during embryonic and fetal development 
and later, during puberty. Female reproductive disorders in adulthood can originate from 
interference with hormone levels and function during development, as was clearly demonstrated by 
the “DES disaster”, where overt reproductive effects have been described in children born from 
women taking the synthetic oestrogen diethylstilbestrol (DES) as a drug during pregnancy. The 
adverse health effects include a rare form of vaginal cancer in girls, increased incidence of uterine 
fibroids, endometriosis, impaired fecundity and earlier age at menopause [11]. Startlingly, 
reproductive effects are still apparent in women whose mothers have been prenatally exposed to DES 
[12]. 
In the transition from (unborn) child to an adult woman, many hormonal processes are activated 
or reactivated. This means that basic biology of the female reproductive system is very different in 
the embryo, fetus, newborn, young girl, adolescent, and adult women. Consequently, the effect of 
EDC exposure on the female reproductive system depends on the age or life stage when exposure 
occurs (Figure 1). In addition, the effects of EDC exposure during early life may be activated or 
worsened by additional EDC exposure throughout a woman’s life. 
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Figure 1. Stages of oocyte development: disruption by EDCs at different life stages leads to different 
reproductive effects in women. EDC, Endocrine Disrupting Chemical. 
2.3. In the Womb 
At birth, a baby girl has per ovary approximately 300,000 primordial follicles containing 
immature eggs or oocytes, which constitutes the ovarian reserve [13]. The human ovarian reserve is 
finite, as was recently demonstrated by the lack of oocyte stem cells in single-cell analyses of adult 
human ovaries, demonstrating that lost oocytes cannot be replaced [14]. This clearly shows that the 
number of oocytes is a major limiting factor in human reproduction. The ovarian reserve is 
established through a series of critical steps during development: after migration of the primordial 
germ cells from the proximal epiblast to the primitive gonadal structure, the bipotential gonad 
differentiates into an ovary in embryos with the female genotype (XX). Next, germ cell nest formation, 
meiotic division (until prophase I stage), and primordial follicle assembly (involving nest breakdown, 
germ cell death, and formation of primordial follicles) take place, leading to the establishment of the 
maximal ovarian reserve at birth. The possible actions of chemicals, including EDCs such as BPA and 
bis(2-ethylhexyl) phthalate (DEHP), on the developing oocytes and ovary have been described in a 
review by Johansson et al. [15]. During pregnancy, human fetal adrenals are essential for steroid 
hormone production. Strikingly, the hypothalamic-pituitary-adrenal axis of the female seems more 
susceptible to early-life programming than that of the male [16] and thus potentially for EDCs. 
Several in vitro studies show interaction of EDCs with adrenal steroidogenesis, which differs from 
interactions with gonadal steroidogenesis [17,18]. However, how this affects female programming of 
the reproductive system is unknown. Undeniably, there are gaps in our scientific understanding on 
how disrupted endocrine and developmental processes during specific life-stages can affect ovarian 
and oocyte development and fertility. 
2.4. Puberty 
In girls, puberty typically starts between the age of 10–14 years, and is activated by hormonal 
signalling. Puberty is characterised by ovarian and adrenal maturation. The transition into puberty 
is driven by the reactivation of the pulsatory release of gonadotropin-releasing hormone (GnRH) by 
the hypothalamus leading to gonadarche—i.e., ovarian maturation—increased sex steroid 
production and initiation of adult pattern folliculogenesis. In humans, ovarian development in 
puberty is preceded by adrenarche, the maturation of the adrenal cortex, and associated increased 
secretion of the adrenal androgens dehydroepiandrosterone (DHEA) and its sulfate (DHEAS). This 
adrenarche component of puberty is unique to humans and some other higher primates. Both 
hormonal signalling and pubertal onset are susceptible to disturbances resulting from EDC exposure. 
Several studies have shown that early-life exposure to DES interferes with the programming of 
pulsatile GnRH secretion and feedback regulation at a time when endogenous oestradiol levels are 
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low [19]. Likewise, changes in GnRH pulsatory release are seen upon postnatal exposure to 
phthalates and BPA in rodent studies [20–22]. This makes it highly probable that EDCs may affect 
pubertal onset in girls. The windows of sensitivity appear to be the prenatal and early postnatal life 
as well as puberty itself [23]. Globally, a trend toward earlier onset of puberty has been observed in 
girls. However, epidemiological studies show mixed results in relation to chemical exposures, with 
some exposures being associated with earlier timing of puberty in girls, and some with later [24]. 
Additionally, associations between EDCs and early breast development in girls has increasingly been 
described over the last decade [25,26]. In rats, indicators of cancer induction were observed in 
mammary glands after prenatal or neonatal exposure to BPA [27,28]. Clearly, EDCs can affect 
processes that mark the beginning of puberty. Yet, the exact processes that trigger the aforementioned 
effects on puberty and the influence EDCs may have thereon, still need to be clarified. 
2.5. Adulthood 
During a woman’s reproductive years (typically between 15 and 49 years of age), approximately 
400 follicles will mature to the ovulatory stage until menopause marks the end of the ability to 
conceive a child. Each month, several primordial follicles will start to mature, but typically only a 
single oocyte completes the maturation process (folliculogenesis) every month. The follicles that do 
not complete folliculogenesis will die by atresia. During folliculogenesis, a follicle expands in size via 
oocyte growth, granulosa cell proliferation, theca cell recruitment from the stroma, and their 
subsequent proliferation. The granulosa cells synthesise oestrogens from the androgens supplied by 
the theca cells. Similar to the human testis, an alternative steroid producing pathway (“backdoor 
pathway”) is suggested based on gene and protein expression profiles [29]. However, actual levels of 
these backdoor steroid hormones and their roles in reproductive processes have not yet been 
demonstrated in the female. Moreover, it is yet to be determined how the production of hormones in 
the ovary specifically is affected by EDCs. 
To maintain the periodical maturation and ovulation of oocytes and have a regular menstrual 
cycle, correct signalling of the hypothalamic-pituitary-gonadal (HPG) axis is an essential prerequisite. 
This ensures that the ovaries produce appropriate levels of hormones at the correct time. In mammals, 
including humans, the HPG axis is under negative- and positive feedback control of the sex steroids. 
An enigmatic feature in women is the switch from negative- to positive-feedback actions of oestradiol 
in the preovulatory phase, leading to a luteinizing hormone (LH) surge that triggers ovulation [30]. 
It is clear though, that some EDCs can affect menstrual cyclicity. For example, an in-depth review 
clearly shows that an alteration of the HPG axis regulation of oestrogens by BPA is an essential 
mechanism underlying the observed menstrual cycle irregularities observed with BPA exposure [10]. 
Some studies show that the rate of folliculogenesis and steroidogenesis are reduced in women treated 
with ketoconazole during fertility treatment [31,32]. Furthermore, a few small-scale studies indicate 
that EDCs, such as perfluorinated compounds and other persistent organic pollutants, in follicular 
fluid affect oocyte competence and artificial fertility treatment success [33]. Whether EDCs can affect 
growth and/or maturation of follicles or accelerate their loss has not yet been thoroughly addressed. 
3. Advancing Test Methods for EDC Identification in Chemical Regulations 
In order to achieve the main goal of FREIA and improve test methods for identification of EDCs 
that cause female reproductive toxicity, we need human-relevant biomarkers for ovarian toxicity 
spanning fetal development to childhood, puberty, and adulthood. The FREIA project has a keen 
focus on molecular characterisation of human ovarian and adrenal tissues and how they are affected 
by EDC exposure. In uniquely powered human fetal studies, ovaries and adrenals from elective 
terminations of normally-progressing pregnancies are being used, along with ovarian tissue donated 
by adult patients. In FREIA, we culture these human tissues in vitro and expose these to selected 
chemicals, i.e. DES (to target oestrogen receptor) and ketoconazole (to target steroidogenesis). Next, 
we analyse effects on morphological, protein, endocrine, and transcriptional level using a range of 
test methods. The focus on both human ovary and adrenal is important here, considering that the 
human fetal zone is not replicated in routine test animals. Moreover, steroidogenic pathways appear 
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to be tissue-specific, as depicted above, and sex-specific. For example, in the second trimester, 
circulating levels of the major adrenal hormone DHEA in the female human fetus are not significantly 
different from serum and testicular levels the male at the same age, while intra-ovarian levels are 
much lower [34]. The outcomes of the human tissue studies will be extremely valuable in assessing 
sensitive windows of exposure and human-specific biomarkers of developmental perturbation. We 
also include two existing fertility treatment patient cohorts from Sweden and Estonia in the FREIA 
project. These cohorts enable us to assess EDC levels in follicular fluid and gene expression in 
granulosa cells and link these with fertility treatment outcome. Previous small-scale studies of 
women visiting fertility clinics have shown that human follicular fluid samples contain a wide array 
of chemicals with endocrine activity, such as dichlorodiphenyltrichloroethane (DDT), phthalates, 
BPA, and perfluorinated compounds, indicating direct exposure of maturing oocytes and their 
surrounding steroid-producing cells [33,35–37]. In addition, we carry out rodent in vivo studies, 
enabling us to link changes in molecular and cellular markers in the ovary, adrenal and 
hypothalamus during different developmental stages with actual fertility parameters in adult 
animals. Together, the outcomes of the human and animal studies will provide toxicity signatures for 
EDC-associated female reproductive toxicity. These toxicity signatures will be made publicly 
available in the TOXsIgN database [38] and can be used as scientific basis for the development of a 
strategy to address female reproductive toxicity. 
3.1. Mechanistic Descriptions of Female Reproductive Toxicity 
There is a global trend to move away from standardised animal-based testing for endocrine 
disrupting properties of chemicals to more human-relevant methods that are based on our 
understanding of mechanisms of toxicity. To date, studies reporting associations between exposure 
to EDCs and altered development or function of the ovaries with female reproductive toxicity are, 
perhaps inevitably, mostly descriptive. Thus, they provide limited information on the mechanisms 
driving the effects caused by EDCs. This is problematic since we need mechanistic understanding to 
adhere to the recently adopted criteria for identification of pesticides and biocides with endocrine 
disrupting properties. These criteria require information on the endocrine mode of action of a 
chemical, the adverse effect and a ‘biologically plausible link’ between the endocrine mode of action 
and the adverse effect [39]. A solution to this challenge could be to create conceptual frameworks to 
describe the progression of an adverse outcome, from its molecular initiating event (MIE) to 
secondary, tertiary, and downstream cascading key events (KEs) at the cellular, tissue, or organism 
level leading eventually to a pathology or adverse outcome, termed an “Adverse Outcome Pathway” 
(AOP). For female reproduction, this type of information is very limited. The AOPWiki, an open-
source database for AOPs, only contains one description of female reproductive toxicity 
(https://aopwiki.org/aops/7), which is mainly based on rodent data. It pertains to reduced aromatase 
levels leading to reduced oestrogen synthesis, altered cyclicity, and ultimately impaired fertility. 
Clearly, this is severely inadequate in covering the different susceptible windows and molecular 
pathways that most likely will underpin EDC-related female reproductive toxicity in humans. 
To address this obvious shortcoming, we will start by compiling putative AOPs (pAOPs) for 
female reproductive toxicity with a focus on ovarian development and function (Johansson et al., 
submitted for publication). These pAOPs will guide our efforts towards pinpointing test methods 
that can best capture key events targeted by chemicals and leading up to female reproductive 
disorders. They will also highlight important knowledge gaps that we need to focus on in the years 
to come to elaborate a more robust testing strategy aimed at safeguarding women’s reproductive 
health. Specifically, we intend to use the newly constructed pAOPs to develop an integrated 
approach to testing and assessment (IATA) or ‘FREIA test strategy’ for female reproductive toxicity. 
Ultimately, this will enable us to prepare a guidance document that describes how to use and 
interpret the FREIA test strategy on female reproductive toxicity (Figure 2). 
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Figure 2. Experimental studies performed in the FREIA project will enable improved understanding 
of the harmful effects of endocrine disrupting chemicals (EDCs) on female reproduction. These 
studies will provide human-relevant biomarkers and adverse outcome pathways (AOPs) that will be 
used to develop dedicated test methods to identify EDCs that cause female reproductive toxicity. 
Furthermore, these advances will lead to a strategy around implementation of the new or improved 
AOPs and test methods within in regulatory chemical safety assessment. 
3.2. Dedicated Endpoints and Bioassays to Address EDC-Related Female Reproductive Toxicity 
A better mechanistic understanding of the processes that direct normal ovarian development 
and function will help us identify the best test methods that are needed to capture key steps leading 
to female reproductive disorders, which is the ultimate goal of FREIA. Considering that chemical 
safety assessment is still largely dependent on in vivo rodent studies, it is important to characterise 
relevant endpoints and maximise predictivity for female reproductive toxicity in these studies. Some 
in vivo endpoints that FREIA addresses are listed below (this is not intended to be an exhaustive list). 
In addition, we will explore the potential to include these (optimised) endpoints in existing OECD 
test guidelines, when deemed feasible. 
(1) Ovarian follicle counts performed in adult animals is included in selected OECD test guidelines, 
including the Extended One-Generation Reproductive Toxicity Study (TG 443). FREIA aims to 
improve follicle counting as currently recommended methods are highly affected by the size of 
the ovary and does not necessarily reflect the total follicle number. 
(2) Comparison of gene expression changes in key cell types in rat ovaries and in granulosa cells 
from human follicular fluids will help us to find biomarkers for oocyte quality, which are 
currently lacking in OECD test guidelines. 
(3) Morphological changes in early mammary development by image analysis of mammary gland 
whole mounts are considered sensitive markers of endocrine disruption in female rodents, yet 
is currently not part of any OECD test guideline. We will improve whole mount examination in 
the rat mammary gland. An unbiased and sensitive software tool will be applied for examination 
of mammary gland whole mounts collected at young age [40]. 
(4) Puberty is a time with great hormonal changes, including a dramatic increase in DHEA over the 
adrenarche, yet this is largely overlooked in current test strategies dealing with EDCs. In FREIA 
we will evaluate the need for implementation of elements of the female pubertal assay, an 
established protocol (US EPA OPPTS 890.145), into current or future OECD test guidelines. 
(5) Changes in GnRH secretion preceding pubertal onset is considered a key event in ovarian 
dysfunction after EDC exposure. The effects of DES and ketoconazole on pulsatile GnRH release 
and hypothalamic transcriptional markers will be studied in primary rodent hypothalamic 
explants and compared with effects on GnRH release of in vivo exposed hypothalamus. This will 
allow the study of effects of prenatal exposure on the programming of maturation of GnRH 
secretion. 
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In FREIA, we use carefully designed, fit-for-purpose in silico and in vitro models with relevant 
cell types to experimentally assess and quantify putative molecular and cellular events underlying 
EDC-induced female reproductive toxicity. These models will be optimised, and standardised 
protocols will be provided at the end of the FREIA project. These include, but are not limited to:  
(1) Quantitative structure-activity relationships (QSARs) allow us to predict molecular targets 
based on physico-chemical properties of a chemical. We will improve existing QSARs for 
aromatase and PPAR-gamma, two of the key events in a proposed adverse outcome pathway 
for female reproductive toxicity. These QSAR models and predictions will be made publicly 
available via the freely available DTU Danish (Q)SAR database (http://qsar.food.dtu.dk/) to open 
the possibility of integrating dedicated QSARs into toxicological risk assessment strategies. 
(2) Oestrogen receptor ER-beta (ESR2) plays a central role in ovarian development and function 
[41], yet concentration-effect data of EDCs on this receptor is limited. A high content analysis 
(HCA) assay utilizing an enhanced green-fluorescence tagged ER-beta nuclear receptor 
transfected into the U2OS cell line will be optimised and employed for screening of selected and 
human relevant EDCs over a concentration range for ER-beta concentration-response activity.  
(3) G-coupled protein oestrogen receptor (GPER) is suggested to act as selector during 
folliculogenesis [42] and may be involved in various ovarian pathologies [43]. GPER is also often 
more highly expressed in human fetal tissues than ER-alpha (ERS1) or ESR2. A novel high 
content analysis (HCA) assay for the GPER will be developed alongside HCA assays to assess 
subtle pre-lethal cytotoxicity in female reproductive cells.  
(4) It is not known whether the standardised steroidogenic assay OECD TG 456, which uses the 
adrenal corticocarcinoma cell line H295R and focuses only on progesterone, testosterone, and 
oestradiol synthesis, is sufficiently applicable to describe (interactions with) ovarian-specific 
steroidogenesis. This issue will be clarified by comparing steroidomic profiles obtained from 
human fetal ovarian and adrenal gland cultures, adult primary human ovarian tissue cultures, 
and human-derived granulosa cell lines.  
(5) For obvious ethical reasons, in vitro studies to assess human oocyte maturation and competency 
after fertilisation cannot be used for routine screening of EDCs in a regulatory context. In 
contrast, bovine ovarian tissues and follicles can easily be obtained from slaughterhouses. From 
these collected follicles, oocytes can be isolated and matured and used for in vitro fertilisation 
experiments, where embryonic development can be followed routinely until blastocyst hatching 
and elongation. Several studies have demonstrated the value of such bovine oocytes as 
experimental model for human reproductive parameters [44]. This test method adheres fully to 
the 3R-principle of toxicity testing in the 21st Century. Bovine oocyte studies will be performed 
to assess the effects of EDCs on oocyte maturation and the post-fertilisation competence to 
develop into a healthy embryo will be explored. 
3.3. Testing for EDCs in the Regulatory Context 
In the European Union, chemicals have to go through a safety evaluation before being allowed 
on the market. The type of information that needs to be provided by industry to the regulators, 
however, depends as much on the production volume and intended application for the chemical as 
on its inherent properties. In other words, the required toxicity tests depend on whether a chemical 
is a pesticide, biocide, food additive, cosmetics additive, or an industrial chemical. Specific criteria 
and guidance for identification of EDCs only exist for pesticides and biocides [39]. In the REACH 
regulation, endocrine disrupting properties of industrial chemicals are currently assessed case by 
case for substances of very high concern and is based on existing scientific evidence and expert 
opinion. Other regulations addressing the safety of chemicals in everyday products—such as 
cosmetics, toys, or food contact materials—currently do not have specific identification processes for 
EDCs. Obviously, there is still much to gain in regulatory procedures and risk management strategies 
for EDCs, and improved test capabilities will certainly contribute to better protection of health and 
the environment [45]. As described above, FREIA aims to improve capabilities for EDC identification 
in chemical regulations by providing improved or additional endpoints in existing OECD test 
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guidelines and provide new assays. We work closely with seven other EU-funded projects in a cluster 
called EURION. The other projects in the EURION cluster develop test methods to identify EDCs that 
cause thyroid hormone disruption, developmental neurotoxic effects, and/or metabolic diseases. 
Together, these projects will provide robust test methods that have the potential to improve EDC 
identification in various regulatory chemical frameworks. Internationally, we are faced with the 
added problem that chemical regulation and legislation is different in different parts of the world. 
Here, the International Advisory Panel of the EURION cluster may play a role by providing a bridge 
to other European and international initiatives and regulatory bodies. The FREIA consortium is a 
proponent of a more harmonised regulatory framework that puts people’s health at the forefront, 
irrespective of where in the world the individual happens to reside or what application a specific 
chemical was intended for. 
4. Sharing and Safeguarding 
Clearly, the outcomes of the FREIA project will significantly improve our understanding of 
female reproductive toxicity and, more specifically, how EDCs contribute. Together with outcomes 
of the European Human Biomonitoring Initiative (HBM4EU) and the Scottish Advanced Fetal 
Research (SAFeR) Study, we can make important contributions to our understanding of how lifestyle 
factors can influence EDC-related disease risk, specifically regarding female reproductive health. 
While EDC exposures during early development might prime a woman’s predisposition to 
compromised reproductive health, these effects can be amplified through additional exposures or 
lifestyle factors after birth. After all, the ovarian reserve should last for decades, yet, it is continuously 
exposed to EDCs. The scientific knowledge generated in the FREIA project will provide openings to 
map out options to improve female reproductive health, for example through lifestyle choices that 
may reduce exposure to EDCs. These options will be discussed with relevant stakeholders and 
gathered in a health promotion strategy that builds on existing expertise (e.g., from the WHO, EFSA, 
EPA) and (grass root) initiatives, such as “toxin-free Stockholm” 
(miljobarometern.stockholm.se/miljogifter/kemikaliecentrum/). We have established partnerships 
with major actors in policy and advocacy on (women’s) health protection. These include the Health 
and Environment Alliance (HEAL), the International Federation of Gynecologists and Obstetrics 
(FIGO), and the International Federation of Fertility Societies (IFFS). These partnerships allow us to 
communicate our scientific findings in light of the importance of a healthy lifestyle and a sustainable 
environment, and to inform society how to avoid the potential health risks associated with EDCs. 
5. Conclusions 
The main objective of the FREIA project is to provide dedicated, human-relevant, test methods 
to identify EDCs that cause female reproductive toxicity, before the end of 2023. The FREIA 
consortium consists of 11 partners with outstanding scientific and regulatory expertise on endocrine 
disruption in relation to women’s reproductive health, early life development, epidemiology, 
endocrinology, and toxicology. Our combined expertise, the availability of human female tissues, 
together with advances in international AOP frameworks, provide an unparalleled opportunity to 
improve existing test methods and develop dedicated novel in vitro and in silico methods to identify 
EDCs that affect female reproductive health. The FREIA project has a strong focus on developing test 
methods and strategies that have the widest reach and at the same time are harmonised enough to 
allow inclusion in internationally validated and accepted guidelines, such as the OECD TG 
conceptual framework for testing and assessment of endocrine disruptors [5]. Moreover, the FREIA 
project aims to identify and close some knowledge gaps by providing increased understanding of 
female reproductive toxicity, which can be used by scientists and other stakeholders beyond the 
scientific community to safeguard women’s reproductive health against EDCs. Obviously, the FREIA 
project will not solve the entire problem of EDC-induced female reproductive disorders, but it is our 
hope, and intention, to at least move the guidepost far enough that the next generation of women is 
better protected against EDCs than the present generation.  
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